KPCB XV Associates’s Atara Biotherapeutics ATRA Stock Holding History

KPCB XV Associates’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$7.09M	Hold	75,066	–	–	19.79%	3
2022 Q2	$14.6M	Hold	75,066	–	–	26.96%	3
2022 Q1	$17.4M	Hold	75,066	–	–	22.56%	3
2021 Q4	$29.6M	Hold	75,066	–	–	23.33%	3
2021 Q3	$33.6M	Hold	75,066	–	–	25.09%	3
2021 Q2	$29.2M	Hold	75,066	–	–	13.03%	4
2021 Q1	$26.9M	Hold	75,066	–	–	11.61%	4
2020 Q4	$36.8M	Buy	+75,066	New	+$34.7M	15.83%	3

Other funds holding ATRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KPCB XV Associates's ATRA Position: Q3 2022 in Review

KPCB XV Associates held its Atara Biotherapeutics (ATRA) position steady in Q3 2022 at 75,066 shares worth $7.09M. The position accounts for 19.79% of the portfolio, ranked #3.

KPCB XV Associates first reported a position in ATRA in Q4 2020 and has held it in 8 quarters since. The position peaked at $36.8M in Q4 2020. 154 funds tracked by Wall St. Rank hold ATRA as of Q3 2022.

KPCB XV Associates held 75,066 shares of Atara Biotherapeutics worth $7.09M as of Q3 2022.
KPCB XV Associates left its Atara Biotherapeutics share count unchanged in Q3 2022.
Atara Biotherapeutics made up 19.79% of KPCB XV Associates's portfolio in Q3 2022, its #3 holding.
KPCB XV Associates first reported a position in Atara Biotherapeutics in Q4 2020 and has held it in 8 quarters since.
KPCB XV Associates's Atara Biotherapeutics position peaked at $36.8M in Q4 2020.
154 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2022.

Based on KPCB XV Associates's 13F filing for Q3 2022, filed 26 Oct 2022.